Dabigatran etexilate: a review in nonvalvular atrial fibrillation

HA Blair, GM Keating - Drugs, 2017 - Springer
Dabigatran etexilate (Pradaxa®) is approved in the EU for the prevention of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and one or more risk …
被引用次数：35 相关文章

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

HA Blair, GM Keating - Drugs, 2017 - europepmc.org
Dabigatran etexilate (Pradaxa®) is approved in the EU for the prevention of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and one or more risk …

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation

HA Blair, GM Keating - Drugs, 2017 - infona.pl
Dabigatran etexilate (Pradaxa®) is approved in the EU for the prevention of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and one or more risk …

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

H Blair, G Keating - Drugs, 2017 - search.ebscohost.com
Dabigatran etexilate (Pradaxa) is approved in the EU for the prevention of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and one or more risk …

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation

HA Blair, GM Keating - Drugs, 2017 - pubmed.ncbi.nlm.nih.gov
Dabigatran etexilate (Pradaxa®) is approved in the EU for the prevention of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and one or more risk …

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation

HA Blair, GM Keating - Drugs, 2017 - search.proquest.com
Dabigatran etexilate (Pradaxa®) is approved in the EU for the prevention of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and one or more risk …